Rehmann Capital Advisory Group’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.24M | Buy |
4,219
+1,035
| +33% | +$340K | 0.06% | 215 |
|
|
2025
Q4 | $1.12M | Sell |
3,184
-680
| -18% | -$230K | 0.06% | 221 |
|
|
2025
Q3 | $1.24M | Buy |
3,864
+332
| +9% | +$103K | 0.07% | 198 |
|
|
2025
Q2 | $1.37M | Buy |
3,532
+69
| +2% | +$27.8K | 0.08% | 164 |
|
|
2025
Q1 | $1.51M | Buy |
3,463
+585
| +20% | +$235K | 0.09% | 156 |
|
|
2024
Q4 | $1.06M | Sell |
2,878
-119
| -4% | -$49.8K | 0.07% | 208 |
|
|
2024
Q3 | $1.57M | Buy |
2,997
+317
| +12% | +$169K | 0.1% | 153 |
|
|
2024
Q2 | $1.45M | Buy |
2,680
+80
| +3% | +$42.3K | 0.1% | 154 |
|
|
2024
Q1 | $1.35M | Buy |
2,600
+649
| +33% | +$323K | 0.1% | 159 |
|
|
2023
Q4 | $920K | Buy |
1,951
+114
| +6% | +$52.7K | 0.08% | 203 |
|
|
2023
Q3 | $800K | Buy |
1,837
+98
| +6% | +$44.5K | 0.07% | 205 |
|
|
2023
Q2 | $773K | Sell |
1,739
-38
| -2% | -$17.5K | 0.07% | 232 |
|
|
2023
Q1 | $817K | Buy |
1,777
+37
| +2% | +$17.6K | 0.08% | 222 |
|
|
2022
Q4 | $893K | Buy |
1,740
+76
| +5% | +$38.6K | 0.09% | 196 |
|
|
2022
Q3 | $756K | Buy |
1,664
+111
| +7% | +$53.1K | 0.08% | 210 |
|
|
2022
Q2 | $750K | Sell |
1,553
-163
| -9% | -$80.6K | 0.08% | 208 |
|
|
2022
Q1 | $843K | Sell |
1,716
-1
| -0.1% | -$457 | 0.08% | 218 |
|
|
2021
Q4 | $796K | Buy |
1,717
+136
| +9% | +$57.2K | 0.07% | 234 |
|
|
2021
Q3 | $586K | Buy |
1,581
+219
| +16% | +$83.2K | 0.06% | 287 |
|
|
2021
Q2 | $526K | Buy |
1,362
+141
| +12% | +$53.9K | 0.05% | 295 |
|
|
2021
Q1 | $438K | Buy |
1,221
+93
| +8% | +$29.9K | 0.04% | 317 |
|
|
2020
Q4 | $362K | Buy |
1,128
+38
| +3% | +$11.7K | 0.04% | 325 |
|
|
2020
Q3 | $293K | Buy |
+1,090
| New | +$293K | 0.04% | 328 |
|
|
2019
Q3 | $800K | Sell |
3,334
-23
| -0.7% | -$6.3K | 0.1% | 109 |
|
|
2019
Q2 | $947K | Buy |
3,357
+158
| +5% | +$43.2K | 0.12% | 139 |
|
|
2019
Q1 | $918K | Sell |
3,199
-108
| -3% | -$31.2K | 0.12% | 133 |
|
|
2018
Q4 | $869K | Buy |
3,307
+65
| +2% | +$17.9K | 0.13% | 87 |
|
|
2018
Q3 | $888K | Buy |
3,242
+2
| +0.1% | +$519 | 0.12% | 142 |
|
|
2018
Q2 | $771K | Buy |
3,240
+2,745
| +555% | +$636K | 0.11% | 154 |
|
|
2018
Q1 | $109K | Buy |
+495
| New | +$116K | 0.02% | 521 |
|
|
2016
Q1 | – | Sell |
-1,505
| Closed | -$210K | – | 375 |
|
|
2015
Q4 | $210K | Sell |
1,505
-37
| -2% | -$5.1K | 0.04% | 313 |
|
|
2015
Q3 | $216K | Buy |
+1,542
| New | +$232K | 0.05% | 290 |
|
Other funds holding ELV
VCM
VPM
Rehmann Capital Advisory Group's ELV Position: Q1 2026 in Review
Rehmann Capital Advisory Group increased its Elevance Health (ELV) stake by 33% in Q1 2026, buying an estimated $340K and bringing the position to 4,219 shares worth $1.24M. The position accounts for 0.06% of the portfolio, ranked #215.
Rehmann Capital Advisory Group first reported a position in ELV in Q3 2015 and has held it in 32 quarters since. The position peaked at $1.57M in Q3 2024. 1,464 funds tracked by Wall St. Rank hold ELV as of Q1 2026.
- Rehmann Capital Advisory Group held 4,219 shares of Elevance Health worth $1.24M as of Q1 2026.
- Rehmann Capital Advisory Group bought 1,035 Elevance Health shares in Q1 2026, an estimated $340K.
- Elevance Health made up 0.06% of Rehmann Capital Advisory Group's portfolio in Q1 2026, its #215 holding.
- Rehmann Capital Advisory Group first reported a position in Elevance Health in Q3 2015 and has held it in 32 quarters since.
- Rehmann Capital Advisory Group's Elevance Health position peaked at $1.57M in Q3 2024.
- 1,464 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.
Based on Rehmann Capital Advisory Group's 13F filing for Q1 2026, filed 15 May 2026.